Why Is Small-Cap Tevogen Bio Stock Rocketing Higher On Thursday?
Why Is Small-Cap Tevogen Bio Stock Rocketing Higher On Thursday?
Earlier this week, Tevogen Bio highlighted the publication of its phase 1 trial data of TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) immunotherapy, published by the journal Blood Advances in August of this year. Data showed:On Thursday, Tevogen Bio Holdings Inc. (NASDAQ:TVGN) announced its top-line revenue forecast for its oncology pipeline, projecting $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $10 billion and $14 billion.
週四，Tevogen Bio Holdings Inc.（NASDAQ: TVGN）宣佈其腫瘤學管道的首要營業收入預測，預計在推出年實現10億美元的營業收入，累計5年估計在100億到140億之間。
Tevogen Bio stock is trading higher with a strong session volume of 62.2 million compared to the average volume of 5.8 million as per data from Benzinga Pro.
Tevogen Bio股票交易量強勁上漲，達到6220萬，較Benzinga Pro數據顯示的平均交易量580萬高。
"This forecast reflects the company's unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come," the company said.
「這一預測反映了公司獨特、更快速、更具成本效益的藥物開發模式，有潛力成爲確保醫療創新可持續發展的藍圖，」該公司表示。
Earlier this week, Tevogen Bio highlighted the publication of its phase 1 trial data of TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) immunotherapy, published by the journal Blood Advances in August of this year. Data showed:
本週早些時候，Tevogen Bio突出了其TVGN 489第1期臨床試驗數據的發表，該試驗爲其探討的異基因SARS-CoV-2特異性細胞毒性CD8+ T淋巴細胞（CTLs）免疫療法，該試驗發表在今年8月的《Blood Advances》雜誌上。數據顯示：
- TVGN 489 was well-tolerated at all four doses tested.
- Nasal swab PCR data showed 88% or greater viral elimination in 92% of patients by day +4 and > 99% in all patients by day +14.
- No progression of disease or the development of Long COVID was observed in the treatment group, despite the prevalence of immunocompromised patients.
- TVGN 489 did not interfere with the development of endogenous anti-SARS-CoV-2 humoral or cellular responses.
- 對所有四個測試劑量，TVGN 489都具有良好的耐受性。
- 鼻拭子PCR數據顯示，截至第4天，92%的患者病毒消除率爲88%或更高，並在第14天時所有患者中超過99%。
- 儘管免疫功能受損患者普遍存在，但治療組未觀察到疾病進展或開多COVID的發展。
- TVGN 489不會干擾內源性抗SARS-CoV-2的體液或細胞反應的發展。
Last week, Tevogen Bio announced updates on its therapeutic pipeline.
上週，Tevogen Bio宣佈了其治療管線的最新動態。
The company said it is pursuing a 'prudent' commercialization strategy with a focus on its ExacTcell technology platform, which leverages precision T-cell therapies to address supportive care for cancer patients.
該公司表示正在實施一個「謹慎」的商業化策略，重點放在其ExacTcell科技平台上，該平台利用精準T細胞療法來改善癌症患者的支持性護理。
Price Action: TVGN stock is up 100.07% at $2.08 at last check Thursday.
股價走勢：TVGN股票在上週四最新交易時上漲了100.07%，報$2.08。
- Novo Nordisk's Weight Loss Drug Ozempic Associated With Reduced Opioid, Alcohol Use Disorder Incidences, Study Shows
- 諾和諾德的減肥藥奧捷匹（Ozempic）與減少濫用阿片類藥物和酒精成癮症發生率有關，研究顯示
Image created using artificial intelligence via Midjourney.
圖像由Midjourney通過人工智能創建。
譯文內容由第三人軟體翻譯。
